Infinitopes

Infinitopes Precision Immunomics is a clinical-stage cancer vaccine biotechnology company spun out of the University of Oxford with support from Cancer Research UK. The company was founded in 2021 and is headquartered at Oxford University's BioEscalator Innovation Building, where it has grown to become the facility's largest tenant. Its work sits at the intersection of precision oncology, AI-driven antigen discovery, and advanced viral vector vaccine technology.

The central challenge Infinitopes was built to address is one that has long frustrated cancer immunotherapy: identifying the right tumour antigens to target, delivering them in a way that generates a durable immune response, and doing so without requiring a bespoke, personalised process for every patient. The company's Precision Immunomics platform uses next-generation LC-MS/MS mass spectrometry combined with proprietary AI and machine learning to identify and rank tumour antigens from real patient tissue — without prior assumptions about which targets matter — enabling the design of off-the-shelf vaccines that can treat broad patient populations.

Its lead product, ITOP1, is a precision therapeutic cancer vaccine designed to prevent recurrence in patients with surgically resectable oesophageal adenocarcinoma. The vaccine leverages the company's high-efficiency viral vector delivery system to drive strong and durable CD8+ cytotoxic T-cell responses against residual tumour cells post-surgery. In April 2025, Infinitopes received Clinical Trial Application approval from the UK MHRA to initiate the VISTA study — a first-in-human, double-blind, randomised, placebo-controlled Phase I/IIa trial across multiple UK NHS university cancer centres.

Infinitopes has raised over $35 million in total seed financing, in rounds led by Octopus Ventures and Amplify Bio. Further co-investors include Cancer Research Horizons, Cancer Research Institute, Kindred Capital, Manta Ray Ventures, Macmillan Cancer Support, Saras Capital, and others. The company has also won two maximum-size non-dilutive awards from Innovate UK — a Cancer Therapeutics Award in 2022 and a Future Economy Investor Partnership in 2023 — and holds an MHRA Innovative Licensing and Access Pathway innovation passport.